By Scott Meacham Copyright © 2018, The Oklahoma Publishing Co. Anybody who’s ever heard me talk about building out Oklahoma’s innovation economy has heard me say that capital begets capital and deal flow begets deal flow. The challenge is that it takes a predictable continuum of investment capital to build a robust pipeline of startups,Read more
News
Scott Rollins, CEO of Selexys Pharmaceuticals/Oklahoman photo provided by OCAST By Jim Stafford Copyright © 2017, The Oklahoma Publishing Co. Selexys Pharmaceuticals president and CEO Scott Rollins reflected on the lessons learned in the wake of the richest transaction in the history of Oklahoma biosciences — the recent $665 million sale of Selexys to industryRead more
By Scott Meacham Copyright © 2016, The Oklahoma Publishing Co. As 2016 draws to a close, entrepreneurs and early stage investors in Oklahoma are ending the year with big smiles. In the past few weeks, the exits of Selexys and WeGoLook have been strong validations that in this state we do have the talent, capitalRead more
By Paula Burkes Copyright © 2016, The Oklahoma Publishing Co. Most scientists spend a lifetime hoping their research contributes to a body of work that collectively will lead to a new drug that will treat or cure a disease. For Oklahoma Medical Research Foundation’s Rodger “Rod” McEver, that body of knowledge was developed in hisRead more
If you are in a decision-making position in an Oklahoma company, is there any reason you wouldn’t want to consider doing business with a startup? You might think that there’s too much risk with a startup. Personally, I like optimism and passion. I favor businesses that stretch, that run lean, and that focus on cashflow. And I like to be part of helping a new business grow. I bet when you think about it, you do too.
If you are in a decision-making position in an Oklahoma company, is there any reason you wouldn’t want to consider doing business with a startup? You might think that there’s too much risk with a startup. Personally, I like optimism and passion. I favor businesses that stretch, that run lean, and that focus on cashflow. And I like to be part of helping a new business grow. I bet when you think about it, you do too.
A global pharmaceutical company will pay up to $665 million for an Oklahoma City research firm that recently completed a large trial of a drug that treats pain among those with sickle cell disease.
A global pharmaceutical company will pay up to $665 million for an Oklahoma City research firm that recently completed a large trial of a drug that treats pain among those with sickle cell disease.
The loss of the state’s EDGE Fund has meant less funding opportunities for the state’s bioscience companies such as Caisson Biotech and Selexys Pharmaceuticals.
